Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of BI 1584862 pharmacokinetics in healthy men
NL-OMON59442Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of BI 1584862, sponsored by Boehringer Ingelheim. Primary endpoint: Primary endpoint(s). Started Jan 2026; status: completed.
02
Drugs
BI 1584862
Beyond the preview
Go deeper on NL-OMON59442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59442.